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Eye Movement Abnormalities in 
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Abstract
Neurodegenerative disorders consist in heterogeneous group of neurological 
conditions characterized by a wide spectrum of clinical features resulting from a 
progressive involvement of distinct neuron populations. Oculomotor abnormalities 
take a key place in the clinical picture of these disorders because the neurodegen-
erative processes involve the brain circuits of eye movements. The most common 
abnormalities include the saccadic dysfunction, fixation instability, and abnormal 
smooth pursuit. The clinical assessment of oculomotor function can help to dif-
ferentiate diagnosis, while electrophysiological measures provide useful biomarkers 
for the understanding of disease physiopathology and progression. In this chapter, 
we review the state of the art of the eye movement’s deficits in some neurodegenera-
tive diseases, such as Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral 
sclerosis, Huntington’s disease, and the hereditary ataxias.
Keywords: eye movements, oculomotor abnormalities, neurodegenerative disorders, 
biomarkers, Parkinson’s disease, Alzheimer’s disease, dementia, hereditary ataxias
1. Introduction
Neurodegenerative disorders encompass a highly heterogeneous group of 
complex neurological disorder characterized by progressive dysfunction and 
loss of neuron populations leading a wide spectrum of clinical features that 
cause notable motor and/or intellectual disabilities regularly incompatible with 
the life [1]. Consequently, some of these conditions represent important public 
health concern and has been identified as a research priority. Although physio-
pathological mechanisms generally differ among neurodegenerative diseases, a 
great number of them are characterized by abnormal accumulation of misfolded 
protein resulting in the loss of their physiological function and/or the gain of toxic 
functions [2, 3].
Classification of neurodegenerative disorders can be established by both the 
cardinal clinical features and the disease proteins (Figure 1). The former charac-
terization distinguishes those conditions characterized by dementia syndromes 
and the movement disorders. Among dementias, the most commonly recognized 
disorder is the Alzheimer’s disease. Other dementia syndromes include the fron-
totemporal dementia, the posterior cortical atrophy, the corticobasal syndrome, 
and others. Movement disorders comprise hypokinetic (such as Parkinson’s 
disease) and hyperkinetic (such as Huntington’s disease) conditions, as well 
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as cerebellar ataxias and motor neuron diseases (such as amyotrophic lateral 
sclerosis) [1, 4].
The protein-based classification includes the tauopathies, the a-synucleinop-
athies, the TDP-43 and FUS proteinopathies, the polyglutamine diseases, and the 
prion disease. Tauopathies are caused by abnormal accumulation of tau protein 
and B-amyloids and are represented by the Alzheimer dementia, whereas among 
the a-synucleinopathies are recognized as the Parkinson’s disease, dementia with 
Lewy bodies, and multisystem atrophy. Abnormal accumulation of TDP-43 and 
FUS proteins defines the physiopathology of the amyotrophic lateral sclerosis and 
frontotemporal lobar degeneration, whereas the polyglutamine diseases result 
from the accumulation of proteins with abnormally expanded polyglutamine 
domains and include the Huntington’s disease; the spinocerebellar ataxias 1, 2, 3, 
6, 7, and 17; the dentatorubral-pallidoluysian atrophy; and the spinal and bulbar 
muscular atrophy. Finally, the Creutzfeldt-Jakob disease is classified as a prion 
disease [1, 4].
Although the phenotypical features of neurodegenerative disorders generally 
differ between distinct disorders due to the differential involvement of specific 
functional systems, most of these conditions are characterized by altered oculo-
motor function as a result of the high vulnerability of the oculomotor system to 
the toxic protein deposition and other physiopathological mechanisms causing 
neurodegenerative diseases [5, 6]. Accordingly, the assessment of oculomotor 
function has become a helpful approach to diagnose some of the neurodegenera-
tive diseases. Besides, eye movements are usually used for monitoring of disease 
progression [6, 7].
This chapter is focused to review the state of the art of the eye movement’s deficits 
in some neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis, Huntington’s disease, and the hereditary ataxias.
Figure 1. 
Classification of neurodegenerative diseases according to cardinal syndrome (A) and disease proteins (B).
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2. Brief overview of eye movements
Eye movements facilitate the clear vision stabilizing images on the retina, 
particularly against head and body movements, capturing and keeping specific 
stimuli on the fovea and aligning the retinal images in the two eyes to ensure the 
single vision and stereopsis. Ocular motility is guaranteed by five basic types of eye 
movements: the vestibulo-ocular reflex, the optokinetic reflex, the saccadic move-
ments, the smooth pursuit movements, and the vergence [8].
Although they differ in various aspects, such as their velocity, reaction time, 
reflexivity/volitional degree, and their neurobiological substrates [9], all have 
generic kinematic properties and share a common final path represented by three 
cranial nerve nuclei and the three pairs of eye muscles that they control [8, 10]. 
Cranial nerve III (oculomotor) innervates the superior, inferior, and medial rectus 
muscles as well as the inferior oblique muscle, whereas trochlear (IV) and abducens 
(VI) nerves innervate the superior oblique and lateral rectus, respectively [10].
The vestibulo-ocular reflex (VOR) is elicited by the vestibular system in 
response to body/head rotations and consists on compensatory eye movements in 
opposite direction to body/head movements to guarantee the image stabilization 
on the retina [11]. When head/body rotations are very large and continued, the 
VOR is depressed, and thus, it is complemented by the optokinetic reflex (OKR), 
in which the speed and direction of a full-field image motion are computed to 
develop eye movements with two phases: a slow phase that alternates with reset-
ting a quick phase [12].
Saccades are ballistic and conjugate eye movements that redirect the fovea from 
one object of interest to another, allowing to explore accurately the visual scenes. 
For that, saccadic system processes information about the distance and direction 
of a target image from the current position of gaze. Saccades are the fastest eye 
movements, reaching up to 800/s. Behaviorally, saccades may be classified as reflex-
guided saccades and intentional or volitional saccades. The first ones are evoked by 
suddenly appearing targets, whereas the second ones, called also as higher-order 
saccades, are made purposefully. Therefore, intentional saccades involve high-
cognitive processing and include voluntary, memory-guided and delayed saccades, 
as well as antisaccades [13, 14].
Smooth pursuit eye movements enable us to maintain the image of a moving 
object relatively stable on or near the fovea by matching eye velocity to target veloc-
ity [10]. Smooth pursuit performance is optimal for target speeds ranging between 
150/s and 300/s, but pursuit velocity can reach up to 100/s [8, 15].
Vergence eye movements are disjunctive movements that provide the binocular 
alignment in response to changing fixation of target distances, requiring that both 
eyes point in contrary directions. These movements are elicited by retinal disparity 
(when a fixation target is not on both foveae) and retinal blur (when a target is not 
in focus). Therefore, these movements are closely related to the lens accommoda-
tion and pupillary reflexes [16].
3. Oculomotor disturbances in neurodegenerative diseases
3.1 Parkinson’s disease and other parkinsonian disorders
3.1.1 Parkinson’s disease
Parkinson’s disease is a progressive disorder pathologically defined by the 
degeneration of the dopaminergic neurons in the substantia nigra and formation 
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of α-synuclein-containing Lewy bodies in the residual dopaminergic neurons. 
Consequently, the clinical picture is characterized by progressive motor symp-
toms that include bradykinesia, muscular rigidity, rest tremor, as well as postural 
and gait impairment. The disease is also associated with many non-motor symp-
toms, some of which precede the motor dysfunction by more than a decade [17]. 
Global prevalence of PD ranges between 100 and 200 cases per 100,000 inhabit-
ants, with an annual incidence around 15 cases per 100,000 [18]. Although the 
etiology of PD is commonly unknown, monogenic causes can be considered in 
5–10% of the cases [19].
Findings about oculomotor function in PD are certainly inconsistent due to 
the reduced number of patients included in the majority of the studies and the 
heterogeneity of the disease phenotype [7]. Nevertheless, saccadic hypometria is 
recognized as the most striking oculomotor feature in PD patients, which can be 
documented both at bedside and by electrophysiological approaches even early in the 
disease course. As a result of the saccade hypometria, PD patients frequently require 
multistep sequences to reach the target [20]. This behavior is more pronounced 
during memory-guided saccades, and it is considered as a disease biomarker [21, 22]. 
The marked saccade hypometria in PD can be explained by the neurodegenerative 
changes in the basal ganglia causing the decrease of pre-oculomotor drive through 
the substantia nigra to the superior colliculus [21]. Alongside the saccade hypome-
tria, PD patients also show abnormally prolonged latency of voluntary saccades such 
as the memory-guided saccades and the antisaccades; nevertheless, the latency of 
externally triggered saccades to visual targets is normal [23]. Distinct to the saccade 
hypometria, the deficits in the saccade initiation are detectable later in the disease 
course and are closely related with the cognitive impairments and the involvement of 
non-dopaminergic pathways such as the frontal and parietal eye fields, the premotor 
cortex, and the lateral prefrontal cortex [24].
The delayed prosaccade and the antisaccade tasks reveal an impaired inhibition 
of saccades as evidence of deficit of automatic response inhibition. PD patients 
show increased timing error rates in the delayed prosaccade paradigm, which 
are closely associated with abnormal neuropsychological performance, whereas 
antisaccade paradigm reveals higher directional error rates [25]. Antisaccade errors 
can be detected early in the disease course [26]. Beyond saccadic impairments, PD 
patients show slight alterations in other eye movements, such as reduced gain of the 
smooth pursuit movements [27] and slow and hypometric divergence movements, 
but normal convergence movements [28].
3.1.2 Other parkinsonian disorders
Oculomotor findings of patients suffering from other parkinsonian disorders 
are varied and usually distinctive to the PD. In cases with multisystem atrophy 
with predominant Parkinsonism (MSA-P), the clinical assessments of oculomotor 
function usually reveal increased square wave jerks, saccade hypometria, as well as 
abnormal smooth pursuit and vestibulo-ocular reflex [29, 30]. Less common ocu-
lomotor features in MSA-P include downbeat nystagmus, head-shaking nystagmus, 
and mild vertical supranuclear gaze palsy [29, 31].
In the progressive supranuclear palsy with Parkinsonism (PSP-P), the most 
important oculomotor feature is the slowing of vertical saccades, which progresses 
to supranuclear gaze palsy in the 70% of the cases but appear lately in the disease 
course than in the classic PSP [32]. In addition, these patients show reduced gains of 
the smooth pursuit movements and saccadic eye movements at similar extent that in 
classic PSP [27].
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3.2 Alzheimer’s disease and other dementias
3.2.1 Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder 
worldwide with a global prevalence above 20 million of affected people, which is 
estimated to grow notably in the next decades. The histopathological hallmark of 
the disease is the deposition of insoluble protein aggregates such as amyloid-β (Aβ) 
plaques and neurofibrillary tangles of tau in the brain, causing a significant brain 
atrophy and subsequent cognitive features such as memory disturbances, execu-
tive dysfunction, difficulties with language, and other cognitive skills that affect a 
person’s ability to perform every day [33]. Similar to PD, the etiology of Alzheimer's 
disease (AD) is not fully understood, but several environmental and genetic factors 
are assumed to contribute to the disease etiopathogenesis [34].
Oculomotor testing in Alzheimer’s disease reveals a varied group of eye 
movement abnormalities, but no specific oculomotor feature is distinguished. 
Among oculomotor features of AD patients, the saccadic intrusions are one of the 
most common [35, 36]. These unwanted microsaccades are mainly oblique and 
can be detected even in subjects with mild cognitive impairment which identify 
this oculomotor feature as a potential biomarker of Alzheimer’s disease at early 
stages [37]. These microsaccades are more frequent in those patients with higher 
dementia scores [38], which support the notion that gaze-fixation instability in 
AD results from the involvement of cognitive processes such as the attention and 
working memory. Nevertheless, the impairment of the saccade pathways could 
also explain the high occurrence of saccadic intrusions, mainly at later disease 
stages [39].
Reflexive and voluntary saccades of AD patients are usually characterized by 
prolonged latencies, reduced velocity, and hypometria. Antisaccadic paradigm 
reveals increased directional error rate alongside with the reduction of the error 
correction, which are closely associated with the severity of dementia [40]. 
Both prosaccadic and antisaccadic alterations in AD are proposed to result from 
impaired inhibitory control and attentional failures, as well as from the later 
involvement of saccadic circuitry at brainstem [39]. In addition, AD patients 
show increased latency to initiate smooth pursuit movements, with decreased 
gain velocity and increased catch-up (compensatory) saccades. Similar to the 
saccadic intrusions and antisaccadic deficits, the rate of compensatory saccades 
during the smooth pursuit is narrowly related with the dementia  
severity [40–42].
3.2.2 Other dementias
In the posterior cortical atrophy (PCA), an atypical variant of AD, the most 
frequent oculomotor abnormalities include increased saccade latency and decreased 
saccade amplitude, but the saccade velocity is normal. Also, the PCA patients show 
increased time to saccadic target fixation, even higher than subjects with typical 
AD. Moreover, these patients show large saccadic intrusions whose frequency is 
correlated with generalized reductions in cortical thickness. Smooth pursuit gain is 
slightly reduced in these patients [43, 44]. Moreover, individuals with frontotem-
poral dementia (FTD) show increased reflexive saccade latency and higher rates of 
antisaccadic errors, but the error correction abilities are preserved. In addition, the 
smooth pursuit movements are characterized by the reduction of gains and accel-
erations [40, 45, 46].
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3.3 Huntington’s disease
Huntington’s disease is a neurodegenerative disorder caused by the abnormal 
expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the hun-
tingtin gene on chromosome 4, encoding the huntingtin protein. The mutation 
results in an excessively long polyglutamine stretch near the N-terminus of this pro-
tein, which identify this disorder as a polyglutamine disease. Mutant HTT affects 
some cellular processes, including protein-protein interaction, protein clearance, 
mitochondrial function, axonal trafficking, gene transcription, posttranslational 
modification, and others that ultimately cause the loss of striatal neurons [47].
Clinically, the disease is characterized by a progressive motor, cognitive, and 
psychiatric disturbance. The motor phenotype includes chorea as cardinal feature, 
as well as dystonia and Parkinsonism, whereas the cognitive dysfunction comprises 
dysexecutive signs, as well as memory and attentional dysfunction. Psychiatric fea-
tures are usually depression, anxiety, apathy, obsessive-compulsive behaviors, and 
others. Similar to other polyglutamine disorders, the age at onset of HD is highly 
influenced by the CAG repeat length, but other genetic and environmental modify-
ing factors are proposed to also control the age at onset variability [47, 48].
Oculomotor abnormalities of patients with HD include saccade slowing and 
deficits in the initiation and suppression of these movements. The reduction of 
saccade velocity appears in around 60% of patients and is commonly observed in 
the vertical plane, but in those cases in advanced disease stages, the saccade slowing 
reaches also the horizontal movements [49, 50]. Saccade latencies are significantly 
prolonged and show a marked variability, which is more pronounced in patients 
showing higher disease severity. Studies using the antisaccadic paradigm have 
revealed and increased rate of directional errors, which are also closely correlated 
with the severity of the disease. Moreover, increases of latency variability and 
timing errors are observed in the memory-guided saccade task. The deficits of the 
suppression and initiation of the saccades can be explained by the neurodegenera-
tive changes in the frontal cortex and in the basal ganglia [51, 52]. So, a recent imag-
ing research revealed a close association between the voluntary saccade inhibition 
deficits and the white-matter corticobasal atrophy in patients [53].
Several authors have evaluated saccadic eye movements in asymptomatic carri-
ers of the HD mutation. These studies have found a significant delay in the initia-
tion of voluntary eye movements, increase in the variability of saccadic latency, and 
increase in the rate of antisaccadic errors [54–56]. A longitudinal follow-up of these 
alterations demonstrated their usefulness as preclinical markers due to the high 
replicability and consistency of these measures [22]. Imaging studies in asymptom-
atic carriers of HD have shown a significant correspondence between alterations in 
saccadic latency and the decrease in the number of fronto-striatal fibers that project 
into the caudate nucleus and the atrophy of gray matter in cortical structures, which 
deepens in the pathophysiology of saccadic alterations in this disease [57, 58]. A 
recent paper demonstrated that the horizontal ocular pursuit item of the Unified 
Huntington’s Disease Rating Scale is useful for detecting differences between 
premanifest individuals and controls [59].
3.4 Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common and devastating 
age-related motor neuron disease, characterized by a progressive loss of upper and 
lower motoneurons, causing paralysis and death in approximately 3 years. The 
pathological hallmark of ALS is the presence of abundant cytoplasmic inclusions 
containing ubiquitin and TDP-43, a RNA-binding protein. The clinical picture 
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comprises progressive muscle weakness alongside hyperreflexia and spasticity 
associated with fibrillations and fasciculations [60]. The disease has a global preva-
lence around five cases per 100,000 inhabitants. Most of ALS cases are sporadic, 
and only the 5% of patients are familial, with at least 12 genes implicated, such as 
the superoxide dismutase 1(SOD1), trans-activate response DNA-binding protein 
(TARDBP), C9ORF72, FUS, and the ataxin-2 genes [61, 62].
Some evidences have demonstrated the involvement of the oculomotor system 
in ALS, leading a broad range of eye movement deficits affecting the saccades and 
the smooth pursuit movements [63–66]. The most prominent and early oculomotor 
alterations of ALS patients are related with abnormal executive oculomotor con-
trol as evidence of frontal lobe involvement. They primarily includes the increase 
of error rates in anti-saccades and delayed saccade paradigms as well as reduced 
voluntary gaze shift and increased number of saccadic intrusions. In general, 
these oculomotor alterations are correlated with the severity of the disease and the 
neurocognitive measures. In a following stage of oculomotor abnormalities, some 
ALS cases can show slow saccades, saccade hypometria, and interrupted smooth 
pursuit, as evidences of the involvement of the brainstem and pre-cerebellar/pon-
tine circuits [67].
3.5 Hereditary ataxias
Hereditary ataxias consist in a heterogeneous group of genetic disorders pheno-
typically characterized by gait ataxia, limb incoordination, dysmetria, dysarthria, 
oculomotor disturbances, and other motor and non-motor features. These disorders 
are associated with atrophy of the cerebellum, which can be accompanied with the 
degeneration of other regions in the central and peripheral nervous system in vari-
ous genetic subtypes [68].
Hereditary ataxias are classified into four main groups regarding their inheritance 
patterns: autosomal dominant (also referred as spinocerebellar ataxias), autosomal 
recessive, X-linked, and mitochondrial ataxias [68, 69]. Till now, 46 subtypes of 
spinocerebellar ataxias have been identified, which imply at least 37 distinct genes 
[70]. The most common subtypes are caused by polyglutamine (polyQ )-coding 
CAG repeat expansions (SCA1,2,3,6,7,17, DRPLA) [71]. Regarding the recessive 
ataxias, nearly 100 genes have been identified, with the highest prevalence for the 
Friedreich’s ataxia (FRDA), caused by GAA repeat expansions or point mutations 
in the frataxin (FXN) [68, 72]. Global prevalence of hereditary ataxias is estimated 
around three cases per 100,000 inhabitants, but there are large regional variations of 
prevalence due to founder effects of some genes [73].
Oculomotor disturbances of SCA patients are varied and result from the 
cerebellar and/or brainstem involvement. The former abnormalities are the most 
common and include the presence of pathological nystagmus, abnormal smooth 
pursuit, and saccadic dysmetria, whereas the impaired VOR, saccadic slowing, and 
ophthalmoplegia are related with pontine degeneration. Nevertheless, the notable 
overlapping of oculomotor features between SCA subtypes implies the requirement 
of other clinical criteria or the genetic testing for sensitively discriminating among 
these diseases [74–78] (Figure 2).
In the case of SCA2, an early and severe saccadic slowing is observed even more 
than a decade before the ataxia onset [79], which identifies it as important preclini-
cal biomarker of the disease. Interestingly, the SCA2 saccade slowing is tightly 
influenced by the expanded CAG repeats in the ATXN2 gene [80] and shows a 
significant familiar aggregation which leads to the suitability of this disease feature 
as endophenotype marker [81], with potential usefulness for the search of modifier 
genes and neurobiological underpinnings of the disease and as outcome measure 
Eye Motility
8
in future neuroprotective clinical trials. Moreover, the saccade slowing in SCA2 
progresses significantly along time providing novel insight into the cumulative 
polyglutamine neurotoxicity and supporting the usefulness of saccade peak veloc-
ity as a sensitive biomarker during the natural history of the disease [82]. Saccade 
pathology in SCA2 is also characterized by abnormal prolongation of reflexive and 
voluntary latencies and increases of the antisaccade error rate. The later feature is 
also detected in prodromal stage and is significantly correlated with the mutation 
size [83–85].
The main eye movement abnormalities of SCA1 patients include saccadic 
dysmetria, gaze-evoked nystagmus, and depressed smooth pursuit [86]. Saccadic 
hypermetria is observed in majority of cases, appears at an early stage of the disease, 
and progresses quickly [75, 76, 87]. SCA3 is characterized by a higher frequency of 
gaze-evoked and rebound nystagmus [88], in addition to decreased smooth pursuit 
gain and saccadic dysmetria. These patients also show decreased VOR gain, which 
correlated with the CAG repeats, suggesting the pathologic involvement of the 
vestibular nuclei in the lateral brainstem [74–76]. Divergence insufficiency and 
strabismus are also common oculomotor features of these patients [89, 90].
In SCA6, a higher frequency of spontaneous downbeat nystagmus and square 
wave jerks is detected [76, 91, 92]. The square wave jerks together with subtle 
abnormalities of saccades and smooth pursuit movements can be detected even 
before the disease onset [93]. The major saccadic alteration in SCA7 is the slowing of 
saccades, together with saccadic dysmetria [94, 95]. These alterations may precede 
cerebellar and retinal manifestations by some years [96]. Patients with SCA17 show 
hypometric saccades which are increased with disease duration but neither with 
ataxia score nor CAG repeats number [97].
Eye movement disturbances are frequent in FRDA. The most prominent 
abnormalities consist in fixation instability such as multiple square wave jerks and 
ocular flutter, which are also complemented by abnormal smooth pursuit, saccadic 
dysmetria, prolongation of saccade latency, gaze-evoked nystagmus, and impaired 
VOR. Interestingly, the prolongation of saccade latency and the square wave jerks 
are significantly correlated with the disease severity and age at disease onset, 
respectively [98, 99]. Moreover, antisaccades and memory-guided saccades are also 
abnormal in these patients as evidence of the disruption of the higher-order pro-
cesses controlling the saccade movements [100].
Figure 2. 
Cerebellar and/or brainstem origin of oculomotor features in SCAs.
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4. Concluding remarks
Eye movement abnormalities are among the most common phenotypic manifes-
tations of patients with neurodegenerative diseases. The prominent features include 
the saccadic abnormalities, fixation instability, and abnormal smooth pursuit. Thus, 
the examination of eye movements is a very useful, but not determinant, approach 
for the differential diagnosis of these disorders. For example, the increased square 
wave jerks and the slowing of vertical saccades may be useful features for the clini-
cians in order to distinguish between the MSA-P and the PSP-P from the idiopathic 
Parkinson’s disease, respectively. In addition, the early and severe saccadic slow-
ing with rare pathological nystagmus distinguishes SCA2 from other autosomal 
dominant ataxias, whereas the marked abnormalities of smooth pursuit, VOR 
and OKR, in association with pathological nystagmus and rare saccadic slowing 
may help to define a SCA6 phenotype. Nonetheless, the notable overlapping of 
oculomotor features between neurodegenerative disorders suggests the necessity of 
other diagnostic criteria for sensitively discriminating among diseases with similar 
symptomatology.
Besides, the assessment of oculomotor function in neurodegenerative disorders 
leads to the identification of disease biomarkers, which acquire key values in the 
clinical and research practice of neurodegenerations. Many eye movement markers of 
neurodegenerative disorders allow to assess the disease stage and disease progression, 
because their changes over time are significantly linked with clinical outcome of syn-
drome severity, and interestingly some oculomotor disturbances precede the clinical 
diagnosis of the disease, which identify them as useful preclinical markers to detect the 
early stages of the neurodegenerative process, to evaluate the genetic susceptibility of 
the asymptomatic relatives, and to identify individuals for enrolment in early interven-
tion trials.
Moreover, the study of eye movements in neurodegenerative diseases offers 
valuable advantages to assess the cognitive functioning in these conditions, mainly 
those measures that reflect the high-order processes underlying the oculomotor 
functions such as the antisaccade and memory-guided saccade task outcomes, the 
saccade latency, and others.
In conclusion, although by decades the oculomotor system has been widely 
studied in neurodegenerative diseases, further efforts are warranted to study their 
involvement in other—less common—disorders, to understand the physiopatho-
logical mechanisms underlying oculomotor disturbances and to certify the role of 
oculomotor features as sensitive outcome measures in further neuroprotective trials.
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